United Therapeutics (UTHR) Short Interest Ratio & Short Volume → Truth about Trump you’ve never heard (From Porter & Company) (Ad) Free UTHR Stock Alerts $269.78 +5.44 (+2.06%) (As of 05/14/2024 ET) Add Compare Share Share Short InterestStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability United Therapeutics Short Interest DataCurrent Short Volume3,850,000 sharesPrevious Short Volume4,320,000 sharesChange Vs. Previous Month-10.88%Dollar Volume Sold Short$902.17 millionShort Interest Ratio / Days to Cover7.4Last Record DateApril 30, 2024Outstanding Shares44,360,000 sharesFloat Size40,890,000 sharesShort Percent of Float9.42%Today's Trading Volume389,190 sharesAverage Trading Volume578,183 sharesToday's Volume Vs. Average67% Short Selling United Therapeutics ? Sign up to receive the latest short interest report for United Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort InterestDays to CoverShort Percent of FloatUTHR Short Interest Over TimeUTHR Days to Cover Over TimeUTHR Percentage of Float Shorted Over Time Ad Banyan Hill PublishingForget the “Magnificent 7” Tech Companies, Buy This AI Stock InsteadThe AI boom continues to snowball with no signs of slowing... Google CEO, Sundar Pichai, made waves during a recent call with analysts, reminding them that the search engine company has been “AI first” since 2016.Get the full story here. United Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 4/30/20243,850,000 shares $902.17 million -10.9%9.4%7.4 $234.33 4/15/20244,320,000 shares $1.02 billion -11.7%10.0%9.4 $235.08 3/31/20244,890,000 shares $1.12 billion +154.7%11.3%11.3 $229.72 3/15/20241,920,000 shares $452.70 million +64.1%4.4%4.7 $235.78 2/29/20241,170,000 shares $264.00 million +0.9%2.7%3 $225.64 2/15/20241,160,000 shares $248.87 million +11.5%2.7%3.3 $214.54 Get the Latest News and Ratings for UTHR and Related StocksEnter your email address below to receive the latest news and analysts' ratings for United Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 1/31/20241,040,000 shares $223.37 million -11.9%N/A3.3 $214.78 1/15/20241,180,000 shares $258.48 million +7.3%N/A3.6 $219.05 12/31/20231,100,000 shares $241.88 million -15.4%N/A3.5 $219.89 12/15/20231,300,000 shares $320.39 million +14.0%N/A4.2 $246.45 11/30/20231,140,000 shares $273.60 million +0.9%N/A4.2 $240.00 11/15/20231,130,000 shares $259.06 million +4.6%N/A4.4 $229.26 10/31/20231,080,000 shares $240.69 million +4.9%N/A3.6 $222.86 10/15/20231,030,000 shares $240.15 million +7.1%N/A3.4 $233.16 9/30/2023962,200 shares $217.33 million -13.3%N/A3.1 $225.87 9/15/20231,110,000 shares $244.47 million +1.8%N/A3.4 $220.24 8/31/20231,090,000 shares $244.55 million -42.3%N/A3.3 $224.36 8/15/20231,890,000 shares $445.53 million +94.6%N/A5.1 $235.73 7/31/2023971,100 shares $235.71 million -2.2%N/A2.7 $242.72 7/15/2023992,600 shares $230.28 million -8.1%N/A2.6 $232.00 6/30/20231,080,000 shares $238.41 million -5.3%N/A2.8 $220.75 6/15/20231,140,000 shares $261.73 million +9.6%N/A2.7 $229.59 5/31/20231,040,000 shares $218.13 million -22.4%N/A2.2 $209.74 5/15/20231,340,000 shares $287.30 million -8.2%N/A2.4 $214.40 4/30/20231,460,000 shares $335.99 million +6.6%N/A2.5 $230.13 4/15/20231,370,000 shares $313.35 million -3.5%N/A2.5 $228.72 3/31/20231,420,000 shares $318.02 million +6.0%N/A2.6 $223.96 3/15/20231,340,000 shares $291.45 million +0.8%N/A2.6 $217.50 2/28/20231,330,000 shares $327.23 million -5.0%N/A2.8 $246.04 2/15/20231,400,000 shares $354.70 million +11.1%3.1%3.6 $253.36 1/31/20231,260,000 shares $331.59 million -3.8%2.8%3.5 $263.17 1/15/20231,310,000 shares $341.96 million -1.5%2.9%3.4 $261.04 12/30/20221,330,000 shares $369.86 million +20.9%3.0%3.5 $278.09 12/15/20221,100,000 shares $303.44 million -17.9%2.5%3 $275.85 11/30/20221,340,000 shares $375.05 million -5.0%3.0%3.6 $279.89 11/15/20221,410,000 shares $365.36 million +6.8%3.2%3.8 $259.12 10/31/20221,320,000 shares $304.30 million -7.0%3.0%3.5 $230.53 10/15/20221,420,000 shares $307.34 million +6.8%3.2%3.9 $216.44 9/30/20221,330,000 shares $278.48 million +7.3%3.0%3.5 $209.38 9/15/20221,240,000 shares $273.59 million +41.4%2.8%3.1 $220.64Trump’s Former Wingman Bets Big on AI (Ad)One of his AI company’s earliest investors was the CIA’s venture capital arm called In-Q-Tel … named after Q, the fictional character who makes gadgets for James Bond. Soon, an alphabet soup of 30 government agencies would entrust the company with their most sensitive information.Get the full story here. UTHR Short Interest - Frequently Asked Questions What is United Therapeutics' current short interest? Short interest is the volume of United Therapeutics shares that have been sold short but have not yet been closed out or covered. As of April 30th, traders have sold 3,850,000 shares of UTHR short. 9.42% of United Therapeutics' shares are currently sold short. Learn More on United Therapeutics' current short interest. What is a good short interest ratio for United Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. UTHR shares currently have a short interest ratio of 7.0. Learn More on United Therapeutics's short interest ratio. Which institutional investors are shorting United Therapeutics? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of United Therapeutics: Twin Tree Management LP, and Concourse Financial Group Securities Inc.. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. What is a good short interest percentage for United Therapeutics? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 9.42% of United Therapeutics' floating shares are currently sold short. Is United Therapeutics' short interest increasing or decreasing? United Therapeutics saw a drop in short interest in the month of April. As of April 30th, there was short interest totaling 3,850,000 shares, a drop of 10.9% from the previous total of 4,320,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is United Therapeutics' float size? United Therapeutics currently has issued a total of 44,360,000 shares. Some of United Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. United Therapeutics currently has a public float of 40,890,000 shares. How does United Therapeutics' short interest compare to its competitors? 9.42% of United Therapeutics' shares are currently sold short. Here is how the short interest of companies in the sector of "medical" compare to United Therapeutics: BioMarin Pharmaceutical Inc. (2.06%), Ionis Pharmaceuticals, Inc. (6.53%), Alnylam Pharmaceuticals, Inc. (2.08%), Madrigal Pharmaceuticals, Inc. (18.67%), Alkermes plc (7.62%), Dr. Reddy's Laboratories Limited (0.52%), Sarepta Therapeutics, Inc. (6.02%), Viatris Inc. (3.84%), Catalent, Inc. (3.67%), Roivant Sciences Ltd. (8.27%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.98 billion), Occidental Petroleum Co. ($3.35 billion), Charter Communications, Inc. ($3.06 billion), General Motors ($2.88 billion), Moderna, Inc. ($2.32 billion), Tractor Supply ($2.27 billion), Royal Caribbean Cruises Ltd. ($2.22 billion), Coinbase Global, Inc. ($2.18 billion), Williams-Sonoma, Inc. ($1.95 billion), and Chesapeake Energy Co. ($1.52 billion). View all of the most shorted stocks. What does it mean to sell short United Therapeutics stock? Short selling UTHR is an investing strategy that aims to generate trading profit from United Therapeutics as its price is falling. UTHR shares are trading up $5.44 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against United Therapeutics? A short squeeze for United Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of UTHR, which in turn drives the price of the stock up even further. How often is United Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including UTHR, twice per month. The most recent reporting period available is April, 30 2024. More Short Interest Resources from MarketBeat Related Companies: BMRN Short Squeeze IONS Short Squeeze ALNY Short Squeeze MDGL Short Squeeze ALKS Short Squeeze RDY Short Squeeze SRPT Short Squeeze VTRS Short Squeeze CTLT Short Squeeze ROIV Short Squeeze Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:UTHR) was last updated on 5/15/2024 by MarketBeat.com Staff From Our PartnersThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldWith revenue forecasted to grow dramatically in 2024 and beyond, this company should be on your radarStocks NewsCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersThe A.I. story nobody is telling you (Read ASAP)TradeSmithBuy this small stock before coming AI Tidal WaveChaikin Analytics